Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Share: Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 – Lipella Pharmaceuticals Inc.

